Celgene, Human Longevity in stem cell deal

Celgene Cellular Therapeutics, a subsidiary of Celgene Corp. (NASDAQ:CELG), granted Human Longevity Inc. (San Diego, Calif.) rights to develop and co-market PSC-100, a placental stem cell population. Celgene will make an undisclosed equity investment in HLI. HLI will sequence and characterize PSC-100.

HLI gains rights for a variety of applications, including sarcopenia, or loss of skeletal mass, which is an aging-associated disease. J. Craig Venter founded HLI in 2013 to build a database of genotypes along with microbiome and metabolomics data for "diseases associated with aging-related human biological decline" (see BioCentury Extra, March 4). ...